Nick Beckett, a specialist in patent and other intellectual property matters, has been made a partner at CMS Cameron McKenna. He joined CMS Cameron McKenna as a trainee in September 1996 and qualified two years later into the technology team. He advises clients in the pharmaceuticals, medical devices, biotechnology, information technology, engineering and other high technology sectors, and his practice includes all areas of intellectual property issues, in relation to patent, design, trademark, copyright/passing-off and confidentiality.
Allibert Helix, the UK manufacturers of chemical handling and storage products, has appointed two new sales managers. Jonathan Hardcastle has become UK sales manager, while Emma Fitch Kemp will be area sales manager across the South. Both bring many years' of experience in a wide range of environmental and technical industries.
Norwood Immunology has appointed Rolf Stahel, the former chief executive of Shire Pharmaceuticals, as non-executive chairman, on admission of the company's shares to the AIM Market of the London Stock Exchange. Stahel has approximately 37 years' experience in the healthcare industry, including at board level in his role as chief executive of Shire Pharmaceuticals. Prior to his role at Shire, he worked for 27 years with Wellcome in Switzerland, Italy, Thailand, Singapore and the UK. His last position with Wellcome was director of group marketing, responsible for group strategy, research and development evaluation, marketing of existing and new products and business development. Richard Williams, ceo of Norwood Immunology, said: 'We are delighted to have been able to attract a chairman of such a high calibre as Rolf Stahel. He brings a wealth of experience to the Board, which will be invaluable to the development of Norwood Immunology.'
Dr Bert S.J. van Toor has joined the investment team of Global Life Science Ventures (GLSV) as investment manager. Dr van Toor has experience in a range of therapeutic areas including global responsibilities in pharmaceutical development at leading big pharma companies such as Boehringer Ingelheim and Bayer. He will operate from the company's Zug office in Switzerland and will be actively involved in evaluating potential investments, developing GLSV's portfolio of companies in the life sciences, and providing further counselling for the management of the fund.